Scotiabank raised the firm’s price target on Arcellx (ACLX) to $133 from $93 and keeps an Outperform rating on the shares. The firm has restored its high conviction that the iMMagine-1 trial results will support anito-cel approval following the departure of the recently installed head of FDA’s Center for Biologics Evaluation and Research, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX:
- Arcellx Advances Phase 3 Study for Multiple Myeloma Treatment
- Arcellx initiated with a Buy at Citi
- Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment
- Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position
- Arcellx Inc’s Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential